3.4.22.26	(D)-Phe-Pro-(D,L)-(4'-guanidino)-Phe-trifluoromethyl ketone	-	97508	
3.4.22.26	(D)-Phe-Pro-(D,L)-Lys-trifluoromethyl ketone	weak	90300	
3.4.22.26	(D)-Phe-Pro-Arg-chloromethyl ketone	-	90301	
3.4.22.26	(NH4)2SO4	76% inhibition at about 40 mM	399	
3.4.22.26	2-Vinylpyridine	-	91201	
3.4.22.26	alpha1-Aantichymotrypsin	weak	2590	
3.4.22.26	alpha2-Macroglobulin	weak	1068	
3.4.22.26	antiCP polyclonal antibody	-	151609	
3.4.22.26	antiFVIIa polyclonal antibody	-	151610	
3.4.22.26	antipain	enhanced in reduced environment	520	
3.4.22.26	antipain	-	520	
3.4.22.26	benzamidine	strong inhibition	579	
3.4.22.26	benzoxycarbonyl-Lys-CHN2	-	92540	
3.4.22.26	CaCl2	91% inhibition at about 40 mM	218	
3.4.22.26	Cu2+	inactivation	19	
3.4.22.26	Cu2+	1 mM: 46% decrease of activity (not statistically significant)	19	
3.4.22.26	diisopropylfluorophosphate	strong	299	
3.4.22.26	E-64	-	559	
3.4.22.26	E64	-	1457	
3.4.22.26	E64	specific inhibition	1457	
3.4.22.26	EDTA	low inhibition	21	
3.4.22.26	Fe2+	in the presence of Ca2+, complete inactivation at 1 mM Fe2+ and above	25	
3.4.22.26	Fe2+	inactivation	25	
3.4.22.26	Hg2+	0.1 mM: 85.5% decrease of activity	33	
3.4.22.26	HgCl2	0.1 mM	110	
3.4.22.26	HgCl2	Hg2+	110	
3.4.22.26	HgCl2	strong, less effective in reduced environment	110	
3.4.22.26	HgCl2	complete inhibition at about 40 mM	110	
3.4.22.26	iodoacetamide	1 mM	67	
3.4.22.26	iodoacetamide	-	67	
3.4.22.26	iodoacetamide	strong, still enhanced in reduced environment	67	
3.4.22.26	leupeptin	-	217	
3.4.22.26	leupeptin	enhanced in reduced environment	217	
3.4.22.26	Mercuric chloride	-	5577	
3.4.22.26	MgCl2	81% inhibition at about 40 mM	196	
3.4.22.26	MgSO4	68% inhibition at about 40 mM	1205	
3.4.22.26	Mn2+	above 1 mM, activates below 1 mM	11	
3.4.22.26	additional information	no inhibition by cystamine, benzoxycarbonyl-Val-Phe	2	
3.4.22.26	additional information	cystatin, alpha1-antiprotease, antithrombin III	2	
3.4.22.26	additional information	no inhibition by alpha2-macroglobulin, alpha1-antiprotease, antithrombin III/heparin, cystatin, cysteamine, alpha1-anichymotrypsin, the effectiveness of most of the inhibitors increase in presence of reducing agents	2	
3.4.22.26	additional information	inhibition by specific anti-CP antibodies	2	
3.4.22.26	additional information	no or poor inhibition by iodoacetamide and E-64	2	
3.4.22.26	N-benzyloxycarbonyl-Phe-Ala-CHN2	-	92541	
3.4.22.26	NaCl	12-21% inhibition, respectively	42	
3.4.22.26	p-chloromercuric benzoate	-	33796	
3.4.22.26	pepstatin A	low inhibition	309	
3.4.22.26	Peptidyl chloromethanes	-	30942	
3.4.22.26	Peptidyl diazomethanes	-	16160	
3.4.22.26	Peptidyl diazomethyl ketones	-	30867	
3.4.22.26	Peptidyl dimethylsulfonium salts	-	46862	
3.4.22.26	Peptidyl sulfonium salts	-	99576	
3.4.22.26	phenylmethylsulfonyl fluoride	-	257	
3.4.22.26	Phenylmethylsulfonylfluoride	strong inhibition	1148	
3.4.22.26	PMSF	-	248	
3.4.22.26	Sn2+	inactivation	413	
3.4.22.26	trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane	i.e. E-64, thiol protease inhibitor, factor X protects	8202	
3.4.22.26	trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane	enhanced in reduced environment	8202	
3.4.22.26	trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane	i.e. E-64, reversible, competitive	1306	
3.4.22.26	trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane	ie.e. E-64, reversible, competitive	1306	
3.4.22.26	trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane	ie.e. E-64	1306	
3.4.22.26	Zn2+	in the presence of Ca2+, complete inactivation at 1 mM Zn2+ and above	14	
3.4.22.26	Zn2+	inactivation	14